MedTrace Logo

Study of the Pharmacokinetics of Golimumab in Moderate to Severe Ulcerative Colitis

NCT02277470 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2015-07-03

No results posted yet for this study

Summary

The purpose of this study is to gain insights in the pharmacokinetics of golimumab in moderate to severe Ulcerative Colitis after subcutaneous administration, during induction and maintenance treatment the investigators will collect blood and stool samples at different time points.

Conditions

Sponsors & Collaborators

  • Onze Lieve Vrouwe Gasthuis

    collaborator OTHER

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Geert R D'Haens, MD, Phd · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • mark lowenberg, MD, Phd · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Ron Mathot, Phd · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-08-31
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02277470 on ClinicalTrials.gov